WS
ALPN

Wedbush Securities’s Alpine Immune Sciences Inc ALPN Stock Holding History

Wedbush Securities’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,000
Closed -$27K – 890
2016
Q4 		$27K Buy
+3,000
New +$59.8K ﹤0.01% 798

Other funds holding ALPN

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Wedbush Securities's ALPN Position: Q1 2017 in Review

Wedbush Securities sold out of Alpine Immune Sciences Inc (ALPN) in Q1 2017, closing a stake of 3,000 shares — an estimated $27K sold.

Wedbush Securities first reported a position in ALPN in Q4 2016 and held it in 1 quarter. The position peaked at $27K in Q4 2016. 28 funds tracked by Wall St. Rank hold ALPN as of Q1 2017.

  • Wedbush Securities reported no remaining Alpine Immune Sciences Inc position as of Q1 2017 after selling out during the quarter.
  • Wedbush Securities sold 3,000 Alpine Immune Sciences Inc shares in Q1 2017, an estimated $27K.
  • Wedbush Securities first reported a position in Alpine Immune Sciences Inc in Q4 2016 and held it in 1 quarter.
  • Wedbush Securities's Alpine Immune Sciences Inc position peaked at $27K in Q4 2016.
  • 28 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q1 2017.

Based on Wedbush Securities's 13F filing for Q1 2017, filed 5 May 2017.